GlassScriptPhysician profile
Frank Joseph Mongillo
NPI 1811917289
$12,579.88
in general payments reported to CMS, 2019-2025
25 companies · $74.91 in 2025
The $74.91 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,766 · 2020: $2,779 · 2021: $825 · 2022: $375 · 2023: $740 · 2024: $1,021 · 2025: $74.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $8,117.11 | 2019-2025 | Sublocade |
| Glaxosmithkline, LLC. | $782.83 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $671.05 | 2019-2024 | Ozempic |
| Amgen INC. | $394.07 | 2019-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $344.67 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $282.32 | 2019-2024 | Fasenra |
| Abbvie INC. | $259.91 | 2021-2024 | |
| Lilly USA, LLC | $237.68 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $222.64 | 2019-2023 | |
| Eisai INC. | $192.57 | 2020-2022 | |
| Braeburn INC. | $162.75 | 2024 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $126.80 | 2021-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $125.00 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $124.79 | 2024 | Inpefa |
| Teva Pharmaceuticals USA, INC. | $119.75 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.94 | 2022 | |
| Redhill Biopharma INC. | $48.09 | 2021 | |
| Orexo US, INC. | $45.10 | 2019-2022 | |
| Allergan, INC. | $39.23 | 2019-2020 | |
| Pfizer INC. | $39.16 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $30.28 | 2024-2025 | Rexulti |
| Tms Neurohealth Centers INC. | $27.91 | 2025 | Tms Neurohealth Centers INC. |
| Horizon Therapeutics Plc | $23.95 | 2019-2022 | |
| Bardy Diagnostics, INC. | $4.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Mongillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.